FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis

FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis

Submitted by admin on September 18, 2024 - 11:03pm
Source: 
Managed Healthcare Executive
News Tags: 
AstraZeneca
Fasenra
eosinophilic granulomatosis with polyangiitis
Headline: 
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
snippet: 

The FDA approved AstraZeneca’s Fasenra (benralizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), according to a news release published today.

Do Not Allow Advertisers to Use My Personal information